1.88
-0.04 (-2.08%)
| Previous Close | 1.92 |
| Open | 1.92 |
| Volume | 153,997 |
| Avg. Volume (3M) | 71,545 |
| Market Cap | 45,024,496 |
| Price / Sales | 0.800 |
| Price / Book | 5.37 |
| 52 Weeks Range | |
| Earnings Date | 27 Jun 2025 |
| Profit Margin | -106.77% |
| Operating Margin (TTM) | -52.24% |
| Diluted EPS (TTM) | -2.64 |
| Quarterly Revenue Growth (YOY) | 49.70% |
| Quarterly Earnings Growth (YOY) | -60.90% |
| Total Debt/Equity (MRQ) | 778.95% |
| Current Ratio (MRQ) | 0.380 |
| Operating Cash Flow (TTM) | -6.40 M |
| Levered Free Cash Flow (TTM) | 10.32 M |
| Return on Assets (TTM) | -17.42% |
| Return on Equity (TTM) | -232.51% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Celularity Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -3.0 |
| Average | -2.38 |
|
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 51.26% |
| % Held by Institutions | 14.66% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| C V Starr & Co Inc | 31 Mar 2025 | 764,069 |
| Keynote Financial Services Llc | 31 Mar 2025 | 25,023 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 09 Jul 2025 | Announcement | Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law |
| 01 Jul 2025 | Announcement | Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies |
| 10 Jun 2025 | Announcement | Celularity Announces Chief Financial Officer Transition |
| 02 Jun 2025 | Announcement | Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology |
| 30 May 2025 | Announcement | Celularity Receives Nasdaq Notice Regarding Form 10-Q |
| 09 May 2025 | Announcement | Celularity Announces Full Year 2024 Operating and Financial Results |
| 25 Apr 2025 | Announcement | Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees |
| 14 Apr 2025 | Announcement | Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |